Sprites
Mein FinanzNachrichtenJetzt AnmeldenPasswort vergessen?
Montag, 28.05.2012Börsentäglich über 11.000 News von 416 internationalen Medien
Erweiterte
Suche
Ad hoc-Mitteilungen

IMMUNOGEN

WKN: 878613  ISIN: US45253H1014  Ticker-Symbol: IMU 
Aktie:
Branche
Biotechnologie
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
IMMUNOGEN Chart 1 Jahr
1-Woche-Intraday-Chart
IMMUNOGEN 1-Woche-Intraday-Chart

Aktuelle News zur IMMUNOGEN Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
16.05. 37
– Trastuzumab emtansine (T-DM1) EMILIA Phase III data selected for plenary session; SAR3419 data and additional trastuzumab emtansine data also being reported – ImmunoGen...
Mehr lesen zu:
ImmunoGen, Inc. Announces Presentations at 2012 ASCO Annual Meeting on Product Candidates with the Company's TAP Technology
10.05. 6
08.05. 27
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the following presentations by...
Mehr lesen zu:
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
27.04. 41
Trastuzumab emtansine (T-DM1) progress includes achievement of progression-free survival (PFS) endpoint in lead Phase III trial for HER2+ metastatic breast...
Mehr lesen zu:
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
18.04. 49
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the Company will host a...
Mehr lesen zu:
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2012 Financial Results
17.04. 4
17.04. 42
Potential new therapeutic for ovarian cancer, non-small cell lung cancer (NSCLC) and other solid tumors which over-express folate receptor 1 (FOLR1). Achievement...
Mehr lesen zu:
ImmunoGen, Inc. Announces the IND Is Now Active for Its Folate-Receptor Targeting Anticancer Compound, IMGN853
17.04. 4
17.04. 49
– First of Two Unique ImmunoGen Product Candidates Expected to Enter Clinic in 2012 – ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology ...
Mehr lesen zu:
ImmunoGen, Inc. Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its Novel IMGN529 Anticancer Compound
30.03. 2
30.03. 2
30.03. 7
30.03. 1
30.03. 1
30.03. -
30.03. -
30.03. 33
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that it will host a conference call at 8:00 am ET on...
Mehr lesen zu:
ImmunoGen, Inc. Announces Conference Call at 8:00 am ET March 30, 2012 to Discuss Today's Favorable Announcements about Trastuzumab Emtansine (T-DM1) and about IMGN901
30.03. 33
NORTH trial assesses impact of adding IMGN901 to standard care for first-line treatment of small-cell lung cancer (SCLC). Trial includes planned...
Mehr lesen zu:
ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 Product Candidate
30.03. 68
WASHINGTON (dpa-AFX) - ImmunoGen Inc. (IMGN) Friday reported positive results from a Phase III trial, dubbed EMILIA, of the anticancer compound transtuzumab emtansine, which the company...
Mehr lesen zu:
ImmunoGen, Genentech Say Breast Cancer Therapy Phase III Trial Results Positive
30.03. 67
Roche has announced lead Phase III trial with trastuzumab emtansine has met progression-free survival endpoint Plans to apply for marketing...
Mehr lesen zu:
ImmunoGen, Inc. Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial
Seite: 1 2 Weiter>>
27 Nachrichten in den letzten 6 Monaten